Alnylam Pharmaceuticals: Data Heavy Catalyst Around AMVUTTRA
Alnylam Pharmaceuticals (ALNY) just put AMVUTTRA in the spotlight, highlighting a substantial package of new clinical and real-world results around transthyretin-mediated amyloidosis that will be presented at two major cardiology and amyloidosis meetings.
Despite the fresh AMVUTTRA data and solid third quarter update, Alnylam Pharmaceuticals has been under pressure, with the share price down 33% over 30 days and 61% year to date, and a 1 year total shareholder return decline of 65%, which points to fading momentum as investors reassess both growth potential and risk around the story.
Scan how other RNA and biotech plays are reacting to this kind of late-stage data shock by reviewing the hand picked 19 high quality undiscovered gems that may still be under the radar.
The recent 61% year to date slide in Alnylam Pharmaceuticals, despite positive AMVUTTRA headlines, forces a simple question: Are you looking at a business problem or a sentiment swing as you think about value next?
Most Popular Narrative: 53% Undervalued
Alnylam Pharmaceuticals closed at $155.94, while the most followed narrative pegs fair value at $331.22 using a 7.67% discount rate and a long term pipeline view that leans heavily on TTR execution.
The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings.
See why 30 investors see Alnylam Pharmaceuticals as 53% undervalued.
Result: Fair Value of $331.22 (UNDERVALUED)
Still, the Alnylam Pharmaceuticals story can flip quickly if AMVUTTRA pricing pressure from 340B and payer pushback persists, or if TTR guidance is cut again.
Find out about the key risks to this Alnylam Pharmaceuticals narrative.
Next Steps
Feeling the tension between risk and opportunity around Alnylam Pharmaceuticals after this AMVUTTRA update and valuation gap story. Act while the data is fresh and judge it on your own terms by weighing the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Alnylam Pharmaceuticals?
You have seen how quickly a story like Alnylam Pharmaceuticals can reset expectations. Do not stop there when other watchlist worthy ideas are just as accessible.
- Spot potential value gaps early and scan the 38 high quality undervalued stocks that align with your return and risk appetite.
- Focus on balance sheet strength first and filter for companies in the list of solid balance sheet and fundamentals (25 results) that can better handle tough conditions.
- Target resilient income streams and review the 7 dividend fortresses if you want yields supported by stronger fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com